Holding(s) in Company

RNS Number : 4962Q
Hikma Pharmaceuticals Plc
29 February 2016
 

For filings with the FCA include the annex


For filings with issuer exclude the annex



TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi



1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached:
ii

Hikma Pharmaceuticals PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights


An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached


An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments


An event changing the breakdown of voting rights


Other (please specify):

New issued share capital affected existing holding percentage

ü

3. Full name of person(s) subject to the
notification obligation:
iii

Darhold Limited

4. Full name of shareholder(s)
 (if different from 3.):iv

Darhold Limited

5. Date of the transaction and date on
which the threshold is crossed or
reached:
v

29 February 2016

6. Date on which issuer notified:

29 February 2016

7. Threshold(s) that is/are crossed or
reached:
vi, vii

25%

 

 

 

 

 

 

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of
shares


if possible using
the ISIN CODE

Situation previous
to the triggering
transaction

Resulting situation after the triggering transaction

Number
of
Shares

Number
of
Voting
Rights

Number
of shares

Number of voting
rights

% of  voting rights x

Indirect

Direct xi

Indirect xii

Direct

Indirect

 

 

GB00B0LCW083

57,933,028

57,933,028

57,933,028

57,933,028

0

24.20%

0



B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial
instrument

Expiration
date
xiii

Exercise/
Conversion Period
xiv

Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.

% of voting
rights







C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial
instrument

Exercise price

Expiration date xvii

Exercise/
Conversion period
xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 





 

 

Nominal

Delta



 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

57,933,028

24.20%

 

 

9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable:
xxi

N/A

 

 

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will acquire:

0

12. Date on which proxy holder will acquire voting rights:

N/A



13. Additional information:


14. Contact name:

Peter Speirs, Company Secretary of Hikma Pharmaceuticals PLC

15. Contact telephone number:

+44 207 399 2772

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUKRSRNRAUUAR
UK 100

Latest directors dealings